The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

Mayo Clinic

Overview

The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000 non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic, tumor, and treatment factors, as well as the interaction among these factors, on short and long-term outcomes. These efforts will identify new approaches to improve the survival and well-being of NHL patients.

Newly diagnosed non-Hodgkin lymphoma (NHL) patients will be recruited from each center participating in the LEO cohort. At time of consent, participants will be asked to completed several questionnaires collecting health history, current medical and quality of life questions. Patients will also provide a baseline blood sample that will processed locally and stored centrally for future research use. Additionally, consent is given for use of excess clinical tumor tissue for research use.

Study Type

OBSERVATIONAL

Conditions

Non-Hodgkin Lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment * Patients may have been treated as long as initial NHL diagnosis is within 6 months of enrollment * 18 years of age or older Exclusion Criteria: * Lymphoma diagnosis greater than 184 days from date of consent

Locations (8)

University of Miami

Miami, Florida, United States

Emory University

Atlanta, Georgia, United States

University of Iowa

Iowa City, Iowa, United States

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Overall Survival (OS)

Time from date of diagnosis to date of death

Time frame: Short (<5 years), medium (5-10 years), and long-term (>10 years)

Secondary Outcomes

Event Free Survival (EFS)

Time from date of diagnosis to date of first defined event (disease progression, relapse or re-treatment for lymphoma, or death)

Time frame: Short (<5 years), medium (5-10 years), and long-term (>10 years)

Lymphoma Specific Survival (LSS)

Time from date of diagnosis to date of death due to lymphoma

Time frame: Short (<5 years), medium (5-10 years), and long-term (>10 years)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.